Glenmark Reports Strong Q1 FY27 Results; Consolidated Revenue Grows 23.1% YoY
Glenmark Pharmaceuticals Ltd., a global research-led pharmaceutical company, announced its financial results for the first quarter of fiscal year 2027, ended June 30, 2026. The consolidated revenue saw an overall growth of 23.1%, reaching Rs. 40,185 million from Rs. 32,644 million in the corresponding quarter last year.The company reported EBITDA at Rs. 8,048 million, marking a 38.6% YoY growth with an EBITDA margin of 20.03%. Profit After Tax (PAT) for the quarter was Rs. 4,828 million, resulting in a PAT margin of 11.8%.Glenn Saldanha, Chairman & Managing Director at Glenmark Pharmaceuticals Ltd., noted that the results reflect strong execution and...